Organization (Hospital)
Maimonides Medical Center
ClinicalTrials.gov lists Maimonides Medical Center as lead sponsor of 50 trials. It has 3 active development programs and 20 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Maimonides Medical Center: 50 lead-sponsored trials and 1 legal-entity registration.
Disease areas (76)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 8 |
| Obesity | 4 |
| Postoperative Pain | 4 |
| Prostatic Neoplasms | 3 |
| Colonic Neoplasms | 2 |
Showing 5 of 76 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 5 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 3 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: none of the 50 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| MINOCYCLINE | Ischemic Stroke | Phase 2/3 | 1 |
| MINOCYCLINE | Hemorrhagic Stroke | Phase 2/3 | 1 |
| MINOCYCLINE | Stroke | Phase 2/3 | 1 |
Approved assets (20)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| +/- Bupivacaine HCl | 4 |
| DEXMEDETOMIDINE | 2 |
| Calcium-vitamin D3 | 2 |
| Guanfacine Extended Release | 1 |
| On-Q Pain Pump | 1 |
Showing 5 of 20 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 18% hit target (n=22) | 53% on time (n=19) |
Journals published in (124)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Academic emergency medicine : official journal of the Society for Academic Emergency Medicine | 5 |
| Diabetes care | 5 |
| Pediatric research | 5 |
| Emergency medicine Australasia : EMA | 4 |
| FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 4 |
Showing 5 of 124 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 7 |
Organization relationships (14)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Moffitt Cancer Center | Co sponsors trial with | 1 |
| California State University System | Co sponsors trial with | 1 |
| Monash University | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| University of California System | Co sponsors trial with | 1 |
Showing 5 of 14 relationships.
Latest dated events (67)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-08-15 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2023-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 67 events.
CLIA clinical laboratory certificates (5)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| MAIMONIDES MEDICAL CENTER | Certificate of compliance | Active |
| MAIMONIDES MEDICAL CENTER | Certificate of waiver | Active |
| MAIMONIDES MEDICAL CENTER | Certificate for PPM procedures | Terminated |
| MAIMONIDES MEDICAL CENTER INC | Certificate of waiver | Terminated |
| MAIMONIDES MEDICAL CENTER | Certificate of waiver | Terminated |
Biomarker capability evidence (18)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FLNB | Trial sponsor | Named in trial inclusion criteria |
| NXF1 | Trial sponsor | Named in trial inclusion criteria |
| AFP | Trial sponsor | Named in trial exclusion criteria |
| CYP3A4 | Trial sponsor | Named in trial exclusion criteria |
| ERBB2 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 18 evidence rows.
Biomarkers this organization publishes on (78)
Shown in this order: most publications first.
Showing 5 of 78 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.